《复牌表现》金斯瑞(01548.HK)初段曾挫27%创逾年半低 涉违反内地进出口规定受查
金斯瑞生物科技(01548.HK)办公地点涉违反中国进出口规定被查,该股今早(22日)复牌大幅低开22.2%,报10.8元後,初段曾跌27.1%,低见10.12元创2019年1月初後逾一年半低;届今早9时52分报10.64元,跌幅逾23%,成交2,984万股,涉3.15亿元。
公司指上周五(18日)起短暂停牌,昨晚(21日)公布,上周四(17日),内地海关缉私部门对集团位於南京和镇江的公司办公地点进行了检查。据了解,检查是关於涉嫌违反中国法律关於进出口的规定。
在调查中,公司董事长、非执行董事兼控股股东之一章方良目前正处於在「监视居住」状态。至今,集团4名其他员工被拘留讯问。相关监管机构尚未提供任何文件表明对章氏的监视居住与他担任公司或任何子公司的高级管理人员或董事有关。公司补充,集团的业务营运维持正常。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.